Adult Dosing

Immunization

• 0.5 mL IM (deltoid/vastus lateralis) x 1
• Give at least 2 wks prior to potential exposure to s. typhi
• Repeat q2 yrs if repeated/continuous typhoid exposure

• For intramuscular use only
• Avoid administration near gluteal area or areas where there may be a nerve trunk
• Prior to administration check visually for any deviation from normal appearance including container integrity
• Prior to use check syringe or vial and its packaging for evidence of leakage, premature activation of the plunger, or a faulty tip seal; on evidence of defects avoid use

Pediatric Dosing

Immunization

2 yrs

• 0.5 mL IM (deltoid/vastus lateralis) x 1
• Give at least 2 wks prior to potential exposure to s. typhi
• Repeat q2 yrs if repeated/continuous typhoid exposure

• For intramuscular use only
• Avoid administration near gluteal area or areas where there may be a nerve trunk
• Prior to administration check visually for any deviation from normal appearance including container integrity
• Prior to use check syringe or vial and its packaging for evidence of leakage, premature activation of the plunger, or a faulty tip seal; on evidence of defects avoid use

[Outline]

• Adult Dosing
• Pediatric Dosing

• Active immunization against typhoid fever in adults and children 2 yrs of age
• Selective immunization against typhoid fever in travelers where risk of exposure to typhoid exists on prolonged exposure to contaminated/food/water, in persons with intimate exposure to a typhoid carrier and persons working with S typhi in microbiological laboratories
• Notes:
• Not indicated for routine immunization
• Not required for international travel, except for travelers to areas such as Africa, Asia, and Central and South america where there is a recognized risk of exposure to s.typhi

• Hypersensitivity to any of the ingredients of the product
• Typhoid fever
• Chronic typhoid carrier

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

See Supplemental Patient Information

• Protects against the infections related to Salmonella typhi, but does not protect against Salmonella paratyphi A or B
• Expected immune response may not be obtained in immunocompromised patients
• May not protect 100% of individuals
• Take utmost care for safe and effective use of vaccine
• Review patient's history to avoid possible adverse reactions. Immediately administer epinephrine injection (1:1000) on occurrence of anaphylactic or other allergic reactions following immunization
• Use separate, sterile syringe and needle or a sterile disposable unit to prevent the transmission of infectious agents from person to person
• Utmost care is necessary to ensure that vaccine is not injected into a blood vessel
• Ask about the recent health status of the patient to be immunized prior to administration of vaccine

Cautions: Use cautiously in

• Thrombocytopenia
• Coagulation disorder
• Acute infection
• Acute febrile illness
• Immunodeficiency
• Combined immunodeficiency disease
• Hypogammaglobulinemia
• Agammaglobulinemia
• Leukemia
• Lymphoma
• Malignancy
• HIV infection
• Antineoplastic therapy
• Concurrent corticosteroids
• Concurrent immunosuppressants
• Anticoagulant use

Supplemental Patient Information

• Inform patients/caregivers about the benefits and risks of immunization with vaccine
• Advise to take necessary precautions to avoid contact with or ingestion of contaminated food and water

Pregnancy Category:C

Breastfeeding: The Centers for Disease Control and Prevention states that vaccines given to a nursing mother does not affect breastfed infants and breastfeeding is not a contraindication to typhoid vaccine. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 20 December 2010). Unknown whether excreted in human milk. Manufacturer advises to use only if the vaccine is of utmost need as no literature is availaible to warrant the use of this product in nursing mothers for passive antibody transfer to an infant.

• CNS: Malaise, headache,
• MUSC: Myalgia
• GI: Nausea, diarrhea, vomiting
• LOCAL: Tenderness, pain, induration, erythema, soreness, impaired limb use
• MISC: Hypersensitivity reactions, anaphylactic reactions, Feverish, decreased activity, flu-like episode, serum sickness

• Vaccine; precise mechanism of action unknown; induces a humoral anti-S. typhi LPS antibody response
• Metabolism: Unknown
• Excretion: Unknown
• Half-life: Unknown

US Trade Name(s)

• Typhim Vi

US Availability

Typhim Vi

• INJ (prefilled syringe): 25 mcg/0.5 mL
• INJ: 25 mcg/0.5 mL vial (20 doses)

Canadian Trade Name(s)

• Typherix
• Typhim Vi

Canadian Availability

Typherix

• INJ (prefilled syringe): 25 mcg/0.5 mL

Typhim Vi

• INJ (prefilled syringe): 25 mcg/0.5 mL

UK Trade Name(s)

• Typherix
• Typhim Vi

UK Availability

Typherix

• INJ (prefilled syringe): 25 mcg/0.5 mL

Typhim Vi

• INJ: 25 mcg/0.5 mL

Australian Trade Name(s)

• Typherix
• Typhim Vi

Australian Availability

Typherix

• INJ (prefilled syringe): 25 mcg/0.5 mL

Typhim Vi

• INJ (prefilled syringe): 0.025 mg/0.5 mL

[Outline]

Allergy & Immunology

Vaccines

Bacterial

Pricing data from www.DrugStore.com in U.S.A.

• Typhim VI 25 MCG/0.5ML SOLN [Syringe] (SANOFI PASTEUR)
  0.5 0.5ml = $65.99
  1.5 0.5ml = $179.98

Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.